[Clinical and economic rationale for the use of bivalos (strontium ranelate) in women with postmenopausal osteoporosis].
The social significance of osteoporosis (OP) is determined by its consequences - fractures of the vertebral bodies and tubular bones. The most serious complication of OP is a fracture of the proximal femur, with which the highest rates of mortality, disability and medical and social costs are associated than with other osteoporetic fractures combined. In 2005, a new drug appeared on the Russia for the treatment of women with OP in the postmenopausal period and for the prevention of peripheral and vertebral fractures - strontium ranelate (bivalos), which simultaneously reduces bone resorption and stimulates bone formation.